What happened

After a big run-up in its share price following better-than-expected earnings and guidance in November, Antares Pharma (NASDAQ:ATRS) shares are down 10% at 3:30 p.m. EDT on Thursday. The company didn't report any news, so today's drop could be a simple case of profit-taking following a nearly 40% gain since October 31.

So what

The company reported it's first quarterly operating profit in history in November, thanks to nearly triple-digit revenue growth following the launch of Xyosted -- a weekly testosterone product -- and Teva Pharmaceutical's (NYSE:TEVA) launch of a generic alternative to Mylan's EpiPen. 

A man staring at a wall covered by drawings of money bags and question marks.


Overall, revenue was up 92% year over year, to $34.3 million in the third quarter of 2019, which resulted in net income of $1 million, or $0.01 per share. Wall Street's industry watchers were expecting sales and earnings per share (EPS) to clock in at $7 million and $0.03 lower, respectively.

Xyosted sales accounted for much of the improvement in sales and profit. An alternative option to using messy gels daily, Xyosted is dosed through an auto-injector once per week. Sales of Xyosted totaled $7 million last quarter. Sales of Otrexup (a subcutaneous formulation of methotrexate) improved to $4.4 million in the quarter from $4.1 million in the same quarter one year ago. 

Revenue from Teva Pharmaceutical associated with its epinephrine product also contributed to sales significantly, lifting partnered-products revenue to $13.2 million from $7.5 million in the year-ago period. The epinephrine product also generated royalties that boosted Antares' companywide royalty revenue 126% year over year, to $8.4 million for the three months ended Sept. 30, 2019.

Now what

The sell-off may offer investors an opportunity to buy shares on sale. The company's third-quarter performance prompted management to boost its full year 2019 sales guidance to a range of between $115 million to $120 million, up from $100 million to $110 million previously.

A tight lid on expenses, an ongoing ramp up in Xyosted, and the potential for Teva Pharmaceutical's generic EpiPen to win more market share could all help Antares Pharma deliver better-than-expected results in 2020. Additionally, Antares Pharma could benefit from a potential launch of Teva Pharmaceutical's generic version of the blockbuster drug Forteo later this year if regulators cooperate, providing yet another important revenue stream. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.